The plasminogen-plasminogen activator (PA) system in neuroblastoma: Role of PA inhibitor-1 in metastasis

Cancer Research

Volumn 59, Issue 6, 1999, Pages 1327-1336

  Sugiura, Yasuo ^a   Ma, Liqun ^a   Sun, Bo ^a   Shimada, Hiroyuki ^a   Laug, Walter E ^a   Seeger, Robert C ^a   DeClerck, Yves A ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; METASTASIS; MICROVASCULATURE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR;

CELL ADHESION; CELL MOVEMENT; ENDOTHELIUM; FIBRONECTINS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; RNA, MESSENGER; STROMAL CELLS; TUMOR CELLS, CULTURED; VITRONECTIN;

EID: 0033559607     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Brodeur, G. M., Seeger, R. C., Barrett, A., Berthold, F., Castleberry, R. P., D'Angio, G., De Bernardi, B., Evans, A. E., Favrot, M., and Freeman, A. I. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J. Clin. Oncol., 6: 1874-1881, 1988.
2. Seeger, R. C., Brodeur, G. M., Sather, H., Dalton, A., Siegel, S. E., Wong, K. Y., and Hammond, D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med., 313: 1111-1116, 1985.
3. Shimada, H., Chatten, J., Newton, W., Jr., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., and Misugi, K. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastoma. J. Natl. Cancer Inst., 73: 405-416, 1984.
4. Reynolds, C. P., and Seeger, R. C. Neuroblastoma. In: C. M. Haskell (ed.). Cancer Treatment. pp. 860-871. Philadelphia: W. B. Saunders, 1994.
5. Meyer, T., and Hart, I. R. Mechanisms of tumour metastasis. Eur. J. Cancer, 34: 214-221, 1998.
6. Woodhouse, E. C., Chuaqui, R. F., and Liotta, L. A. General mechanisms of metastasis. Cancer (Phila.), 80: 1529-1537, 1997.
7. Pepper, M. S. Manipulating angiogenesis: from basic science to the bedside. Arterioscler. Thromb. Vasc. Biol., 17: 605-619, 1997.
8. Vassalli, J. D., and Pepper, M. S. Tumour biology. Membrane proteases in focus. Nature (Lond.), 370: 14-15, 1994.
9. Vassalli, J. D., Sappino, A. P., and Belin, D. The plasminogen activator/plasmin system. J. Clin. Invest., 88: 1067-1072, 1991.
10. Nagase, H. Activation mechanisms of matrix metalloproteinases. Biol. Chem. Hoppe-Seyler, 378: 151-160, 1997.
11. Mazzieri, R., Masiero, L., Zanetta, L., Monea, S., Onisto, M., Garbisa, S., and Mignatti, P. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J., 16: 2319-2332, 1997.
12. Kruithof, E. K. Plasminogen activator inhibitors: a review. Enzyme (Basel), 40: 113-121, 1988.
13. Appella, E., Robinson, E. A., Ulrich, S. J., Stoppell, M. P., Corti, A., Cassani, G., and Blasi, F. The receptor-binding sequence of urokinase. J. Biol. Chem., 262: 4437-4440, 1987.
14. Cesarman, G. M., Guevara, C. A., and Hajjar, K. A. An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. J. Biol. Chem., 269: 21198-21203, 1994.
15. Hajjar, K. A., Jacovina, A. T., and Chacko, J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J. Biol. Chem., 269: 21191-21197, 1994.
16. Olson, D., Polleanen, J., Hoyer-Hansen, G., Ronne, E., Sakaguchi, K., Wun, T. C., Appella, E., Dan, K., and Blasi, F. Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. J. Biol. Chem., 267: 9129-9133, 1992.
17. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., and Chapman, H. A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem., 269: 32380-32388, 1994.
18. Kjoller, L., Kanse, S. M., Kirkegaard, T., Rodenburg, K. W., Ronne, E., Goodman, S. L., Preissner, K. T., Ossowski, L., and Andreasen, P. A. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res., 232: 420-429, 1997.
19. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S., and Loskutoff, D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol., 134: 1563-1571, 1996.
20. Chapman, H. A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol., 9: 714-724, 1997.
21. Waltz, D. A., Natkin, L. R., Fujita, R. M., Wei, Y., and Chapman, H. A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest., 100: 58-67, 1997.
22. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
23. Duggan, C., Maguire, T., McDermott, E., O'Higgins, N., Fennelly, J. J., and Duffy, M. J. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int. J. Cancer, 61: 597-600, 1995.
24. Oka, T., Ishida, T., Nishino, T., and Sugimachi, K, Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. Cancer Res., 51: 3522-3525, 1991.
25. Hasui, Y., Marutsuka, K., Suzumiya, J., Kitada, S., Osada, Y., and Sumiyoshi, A. The content of urokinase-type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. Int. J. Cancer. 50: 871-873, 1992.
26. Nekarda, H., Siewert, J. R., Schmitt, M., and Ulm, K. Tumour-associated proteolytic factors uPA and PAI-1 and survival in totally resected gastric cancer. Lancet, 343: 117, 1994.
27. Mulcahy, H. E., Duffy, M. J., Gibbons, D., McCarthy, P., Parfrey, N. A., O'Donoghue, D. P., and Sheahan, K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet, 344: 583-584, 1994.
28. Bindal, A. K., Hammoud, M., Shi, W. M. Wu, S. Z., Sawaya, R., and Rao, J. S. Prognostic significance of proteolytic enzymes in human brain tumors. J. NeuroOncol., 22: 101-110, 1994.
29. Ganesh, S., Sier, C. F., Heerding, M. M., Griffioen, G., Lamers, C. B., and Verspaget, H. W. Urokinase receptor and colorectal cancer survival. Lancet, 344: 401-402, 1994.
30. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Ronne, E., Hansen, H. H., Dano, K., and Grondahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
31. Paciucci, R., Tora, M., Diaz, V. M., and Real, F. X. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro. Oncogene, 16: 625-633, 1998.
32. Duggan, C., Kennedy, S., Kramer, M. D., Barnes, C., Elvin, P., McDermott, E., O'Higgins, N., and Duffy, M. J. Plasminogen activator inhibitor type 2 in breast cancer. Br. J. Cancer, 76: 622-627, 1997.
33. Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Kramer, M. D., Janicke, F., and Klijn, J. G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin. Oncol., 12: 1648-1658, 1994
34. Reilly, D., Christensen, L., Duch, M., Nolan, N., Duffy, M. J., and Andreasen, P. A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer, 50: 208-214, 1992.
35. Fockens, J. A., Look, M. P., Peters, H. A., van Putten, W. L., Portengen, H., and Klijn, J. G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst., 87: 751-756, 1995.
36. Lim, Y. T., Sugiura, Y., Laug, W. E., Sun, B., Garcia, A., and DeClerck, Y. A. Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. J. Cell. Physiol., 167: 333-340, 1996.
37. Montgomery, A. M., DeClerck, Y. A., Langley, K. E., Reisfeld, R. A., and Mueller, B. M. Melanoma-mediated dissolution of extracellular matrix, contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res., 53: 693-700, 1993.
38. Ades, E. W., Candal, F. J., Swerlick, R. A., George, V. G., Summers, S., Bosse, D. C. and Lawley, T. J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J. Investig. Dermatol., 99; 683-690, 1992.
39. Grannelli-Piperno, A., and Reich, E. A study of proteases and protease-inhibitor complexes in biological fluids. J. Exp. Med., 148: 223-234, 1978.
40. Laug, W. E., Cao, X. R., Yu, Y. B., Shimada, H., and Kruithof, E. K. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res., 53: 6051-6057, 1993.
41. Chirgwin, J. M., Przybyla, A. E., McDonald, R. J., and Rotter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
42. Laug, W. E., DcClerck, Y. A., and Jones, P. A. Degradation of the subendothelial matrix by tumor cells. Cancer Res., 43: 1827-1834, 1983.
43. Menoud, P. A., Debrot, S., and Schowing, J. Mouse neural crest cells secrete both urokinase-type and tissue-type plasminogen activators in vitro. Development (Camb.), 106: 685-690, 1989.
44. Sumi, Y., Dent, M. A., Owen, D. E., Seeley, P. J., and Morris, R. J. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development (Camb.), 116: 625-637, 1992.
45. Sappino, A. P., Madani, R., Huarte, J., Belin, D., Kiss, J. Z., Wohlwend, A., and Vassalli, J. D. Extracellular proteolysis in the adult murine brain. J. Clin. Investig., 92: 679-685, 1993.
46. Hayden, S. M., and Seeds, N. W. Modulated expression of plasminogen activator system components in cultured cells from dissociated mouse dorsal root ganglia. J. Neurosci., 16: 2307-2317, 1996.
47. Tsirka, S. E., Rogove, A. D., and Strickland, S. Neuronal cell death and tPA. Nature (Lond.), 384: 123-124, 1996.
48. Neuman, T., Stephens, R. W., Salonen, E. M., Timmusk, T., and Vaheri. A. Induction of morphological differentiation of human neuroblastoma cells is accompanied by induction of tissue-type plasminogen activator. J. Neurosci. Res., 23: 274-281, 1989.
49. Werb, Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell, 91: 439-442, 1997.
50. Hajjar, K. A., Guevara, C. A., and Dowling, K. Identification of the endothdial cell binding domains of a plasminogen/tissue plasminogen activator receptor, annexin II. Blood, 84: 392a, 1994.
51. Blanchard, S., Barwise, J. L., Gerke, V., Goodall, A., Vaughan, P. F., and Walker, J. H. Annexins in the human neuroblastoma SH-SY5Y: demonstration of relocation of annexins II and V to membranes in response to elevation of intracellular calcium by membrane depolarisation and by the calcium ionophore A23187. J. Neurochem., 67: 805-813, 1996
52. Janicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Hofler, H., and Graeff, H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res. Treat., 24: 195-208, 1993.
53. Pedersen, H., Grondahl-Hansen, J., Francis, D., Osterlind, K., Hansen, H. H., Dano, K., and Brunner, N. Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res., 54: 120-123, 1994.
54. Pyke, C., Kristensen, P., Ralfkiaer, E., Eriksen, J., and Dano, K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res., 51: 4067-4071, 1991.
55. Sordat, I., Chaubert, P., Protiva, P., Guillou, L., Mazzucchelli, L. Saraga, E., Benhattar, J., Tran-Thang, C., Blum, A. L., Dorta, G., and Sordat, B. In situ stromal expression of the urokinase/plasmin system correlates with epithelial dysplasia in colorectal adenomas. Am. J. Pathol., 150: 283-295, 1997.
56. Pepper, M. S., Ferrara, N., Orci, L., and Montesano, R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem. Biophys. Res. Commun., 181: 902-906, 1991.
57. 3 binding to vitronectin. Nature (Lond.), 383: 441-443, 1996.
58. Sugiura, Y., Shimada, H., Seeger, R. C., Laug, W. E., and DeClerck, Y. A. Matrix metalloproteinases 2 and 9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 58: 2209-2216, 1998.
59. Ginestra, A., Monea, S., Seghezzi, G., Dolo, V., Nagase, H., Mignatti, P., and Vittorelli, M. L. Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells J. Biol Chem., 272: 17216-17222, 1997.
60. Baramova, E. N., Bajou, K., Remacle, A., L'Hoir, C., Krell, H. W., Weidle, U. H., Noel, A., and Foidart, J. M. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett., 405: 157-162, 1997.
61. Reynolds, C. P., Tomayko, M. M., Donner, L., Helson, L., Seeger, R. C., Triche, T. J., and Brodeur, G. M. Biological classification of cell lines derived from human extra-cranial neural tumors. Prog. Clin. Biol. Res., 271: 291-306, 1988.